Studies with Two New Phosphodiesterase Inhibitors (ICI 58,301 and ICI 63,197) on Anaphylaxis in Guinea Pigs, Mice and RatsDavies G.E. · Evans D.P.
Imperial Chemical Industries Limited, Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Two compounds, ICI 58,301 (3-acetamido-6-methyl-8-n-propyl-s-triazolo[4,3-a]pyrazine) and ICI 63,197 (2-amino-6-methyl-5-oxo-4-n-propyl-4,5,-dihydro-s-triazolo[l,5-a]pyrimidine) facilitate the recovery of guinea pigs which have been subjected to anaphylactic shock. ICI 63,197 also reduces the amount of histamine released from the isolated lungs of sensitized guinea pigs after injection of antigen, partially inhibits passive cutaneous anaphylaxis in guinea pigs, protects mice from anaphylactic shock, and inhibits passive cutaneous anaphylaxis in rats sensitized with homologous reaginic or heterologous antisera. ICI 58,301 is not active in these conditions. Both compounds are potent inhibitors of 3′:5′-cyclic AMP phosphodiesterase and it is speculated that this property is associated with their anti-anaphylactic effects.
© 1973 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.